Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 2,650 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical Clear all
Completed Phase 2 Interventional Results available

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

NCT02960997
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner, Weber-Cockayne Syndrome
Interventions
Sirolimus, 2%, Vehicle
Drug
Lead sponsor
Stanford University
Other
Eligibility
4 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery

NCT01297959
View directory record Official record
Conditions
Infections
Interventions
E-101 Solution 300 GU/ml, Saline solution
Drug
Lead sponsor
Excited States, LLC
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
34
States / cities
Mobile, Alabama • Los Angeles, California • Stanford, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 23, 2026, 10:29 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Analysis of the Microbiome in Rosacea

NCT04108897
View directory record Official record
Conditions
Rosacea
Interventions
Doxycycline, Ivermectin Topical
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 3 Interventional Results available

P3 Long Term Safety Study of Once Daily SB204 in Acne

NCT02798120
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204 4%
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
9 Years to 99 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
69
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis

NCT03235024
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

NCT02279823
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
CB-03-01 solution, Minoxidil Solution 5%, Placebo solution
Drug
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
San Diego, California • Fridley, Minnesota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

NCT03650361
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.3%, Differin 0.3% Topical Gel, Adapalene Gel 0.3% Vehicle Placebo
Drug
Lead sponsor
Aleor Dermaceuticals Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications

NCT01015638
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin and BPO 5% gel, Clindamycin phosphate and benzoyl peroxide 2.5% gel.
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

VR to Reduce Pain/Anxiety During IV Starts

NCT04942561
View directory record Official record
Conditions
Radiology
Interventions
Samsung Gear VR, Merge VR
Device
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
10 Years to 21 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 4 Interventional Results available

Wound Fluid Protease Levels During Use of Novel Wound Dressing

NCT01567150
View directory record Official record
Conditions
Venous Stasis Ulcers
Interventions
Novel Dressing
Device
Lead sponsor
Hollister Incorporated
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
8
States / cities
Phoenix, Arizona • Miami, Florida • Elk Grove Village, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

NCT03310580
View directory record Official record
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Placebo
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
40
States / cities
Chandler, Arizona • Phoenix, Arizona • Azusa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Applied Topical Heat as an Adjunct for Pain Control in First-Trimester Surgical Abortionl

NCT02536235
View directory record Official record
Conditions
Topical Heat Application for Intraoperative Abortion Pain Management
Interventions
heat
Other
Lead sponsor
Planned Parenthood of Greater New York
Other
Eligibility
16 Years to 51 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 4 Interventional

A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens

NCT01061268
View directory record Official record
Conditions
Dry Eye
Interventions
No topical artificial tear, Blink® Tears Lubricant Eye Drops
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 2 Interventional

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

NCT06309355
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
YR001 ointment, Placebo
Drug · Other
Lead sponsor
Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Boynton Beach, Florida • Hollywood, Florida • Weston, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects

NCT03472547
View directory record Official record
Conditions
Healthy
Interventions
diacerein 1% ointment
Drug
Lead sponsor
Castle Creek Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis

NCT01049243
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluocinonide Cream 0.1%
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 3 Interventional Results available

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults

NCT05014568
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
tapinarof cream, 1%, Vehicle cream
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 2 Interventional

Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma

NCT01693315
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Eye Disease
Interventions
AMA0076, Placebo
Drug
Lead sponsor
Amakem, NV
Industry
Eligibility
30 Years to 85 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Artesia, California • Inglewood, California • Petaluma, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo

NCT03099304
View directory record Official record
Conditions
Vitiligo
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
26
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Rogers, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 23, 2026, 10:29 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED

NCT06542276
View directory record Official record
Conditions
MGD-Meibomian Gland Dysfunction
Interventions
Thermal Vectored Pulsation
Device
Lead sponsor
Dunes Eye Consultants
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dakota Dunes, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

ET-01 in Subjects With Lateral Canthal Lines, LCL-208

NCT03839693
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
botulinum toxin, Type A, Vehicle
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Miami, Florida • Pinellas Park, Florida • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 23, 2026, 10:29 AM EDT
Withdrawn Phase 2 Interventional

Transdermal Continuous Oxygen Therapy for Infection Prophylaxis in High- Risk Patients Undergoing Colon Surgery

NCT02617706
View directory record Official record
Conditions
Anorectal Surgeries
Interventions
Epiflo
Device
Lead sponsor
Neogenix, LLC dba Ogenix
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis

NCT00690833
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
topical desonide hydrogel 0.05%
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
3 Months and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 23, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants

NCT01827358
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Mupirocin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 24 Months
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 23, 2026, 10:29 AM EDT